Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphoma
Calixte Calaud, Emilio M. Serrano-López, Leonie A. Cluse, Izabela Todorovski, Thomas Mardivirin, Matt R. Teater, Abdelillah Maarad, Noura Tawfic, Peter Fraser, Killian Guiraud, Coralie F Dupont, Corinne Ménigot, Ana Carolina Bastos Sant'Anna Silva, David Yoannidis, Timothy J. Semple, , Pilar M. Domínguez
This study shows that combining a HDAC3 inhibitor with 5-Azacitidine enhances anti-tumor effects against DLBCL in vitro and in vivo, with reduced toxicity compared to single agents.
Blood Neoplasia · Mar 2, 2026Peer-reviewedCancer Biology